Literature DB >> 10759400

A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.

C J Ardiet1, B Tranchand, S Zanetta, A Guillot, E Bernard, M Peguy, P Rebattu, J P Droz.   

Abstract

We have developed a specific and sensitive method aiming at docetaxel (Taxotere) determination in plasma of treated patients. This involved solid-phase extraction of 1 ml of plasma onto carboxylic acid (CBA) grafted silica cartridges followed by reversed-phase liquid chromatography with UV detection. The best selectivity was obtained through the use of C18 Uptisphere as stationary phase. The low limit of quantitation obtained (LOQ: 5 ng/ml) allowed measurements of docetaxel up to 24 hours after one-hour infusions with low dosages of drug (60 mg/m2). The method was applied successfully to monitor docetaxel plasma levels within two protocols associating fixed dosages of either methotrexate or gemcitabine with escalating doses of Taxotere.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10759400     DOI: 10.1023/a:1006327302041

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  19 in total

Review 1.  Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry.

Authors:  A Warner; M Privitera; D Bates
Journal:  Clin Chem       Date:  1998-05       Impact factor: 8.327

2.  Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.

Authors:  W J Loos; J Verweij; K Nooter; G Stoter; A Sparreboom
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-06-06

Review 3.  Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.

Authors:  P M Ravdin
Journal:  Eur J Cancer       Date:  1997-08       Impact factor: 9.162

4.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Authors:  M C Bissery; D Guénard; F Guéritte-Voegelein; F Lavelle
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

Review 5.  Antitumor activity of docetaxel.

Authors:  J R Eckardt
Journal:  Am J Health Syst Pharm       Date:  1997-12-15       Impact factor: 2.637

6.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Authors:  R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.

Authors:  M J Glantz; H Choy; W Akerley; C M Kearns; M J Egorin; C H Rhodes; B F Cole
Journal:  Semin Oncol       Date:  1996-12       Impact factor: 4.929

8.  Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography.

Authors:  G Hempel; D Lehmkuhl; S Krümpelmann; G Blaschke; J Boos
Journal:  J Chromatogr A       Date:  1996-09-20       Impact factor: 4.759

9.  Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.

Authors:  V Valero
Journal:  Oncology (Williston Park)       Date:  1997-08       Impact factor: 2.990

10.  Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method.

Authors:  J C Vergniol; R Bruno; G Montay; A Frydman
Journal:  J Chromatogr       Date:  1992-11-06
View more
  1 in total

Review 1.  Clinical pharmacokinetics of docetaxel : recent developments.

Authors:  Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.